Agreement could be worth up to $380M to Neurimmune.

Biogen Idec and Neurimmune Therapeutics entered into an agreement for the worldwide development and commercialization of fully human antibodies for the treatment of Alzheimer’s disease.


The alliance will focus on the development of antibodies that bind to amyloid beta. Neurimmune will conduct research to identify potential therapeutic antibodies using its Reverse Translational Medicine platform. Biogen Idec will be responsible for the development and commercialization of all products. Neurimmune could receive an aggregate of $380M in upfront and success-based milestone payments as well as a royalty on net sales of any products.

Previous articleRosetta and NYU Expand Collaboration to Include Heart Disease
Next articleInhibitex Obtains License to HCV Polymerase Inhibitors